Page 22 - Annual report 2021-22

Annual Report 2021-22 |

patients of pre-ventilation phase as well as of critical phase of the disease with top priority, followed
by trial in non-ICU patients. Further, adalimumab, for which negative evidence from a small RCT alone
was available at the time, was recommended for trial in pre-ventilation as well as critical phases.
Tofacitinib, that has shown benefits in RCT in the non-ventilation phase, may prove beneficial also in
the critical phase of the disease. Canakinumab, with no positive evidence in severe patients not
receiving invasive mechanical ventilation, may exert beneficial effects in less severe, hypoxic patients. 5
These recommendations may motivate experimental studies toward COVID-19 drug repurposing.

“Equipped with his five senses, man explores the universe around him

and calls the adventure science.” — Edwin Powell Hubble